Du offenbarst geradezu alle deine Defizite! Hier der Ausschnitt aus dem Transcript:
Operator [Operator Instructions]: Our first question is over to Christoph Blieffert of Commerzbank.
Christoph Blieffert Commerzbank AG, Research Division: Looking on your acquisitions, is it fair to assume that the focus today is on more healthy, less sick companies than in the years before? And if this observation is correct, this is a strategic shift, and should we expect more kind of these acquisitions going forward? And as a second question, could you share with us your top 4 EBITDA-contributing companies, please?
Dirk Markus Co-Founder, Founding Partner, Chairman of the Executive Board & Group CEO: Okay. So on the first question, these 2 are not necessarily way more profitable than what we used to buy. I mentioned Distrelec Nedis is -- they make a few millions in EBITDA on EUR 275 million in sales, but that's in the 2%, 3% range, and so definitely underperforming where other players in their respective market would be. And looking longer term, you could say that there is a trend for us to buy bigger and healthier businesses over the -- and this trend line going back for the last 15 years since we've existed. The average business we buy today is healthier than the average business we bought 5 and 10 years ago. But healthier is a relative term and we still buy -- and that's our core focus, underperformers. They might not be as sick as they used to be, but there's still definitely underperformers and in companies in a special situation and companies that need intensive presence of the shareholder, and being us and its task -- and our task force to get them to a higher profitability level. So longer-term perspective, yes, healthier, but Distrelec, Nedis and ZIM are not necessarily different from the ones we've bought that -- other companies we've bought recently. The other question was who are the largest profit contributors in the portfolio? To mentioned, and I hope I can get them right and not necessarily in that order, but the bigger ones are now Hanse, Briar Chem, CalaChem, Conaxess, Calumet, Office Depot, I would say those 5, without being able to rank them on a spontaneous basis now, but those are the big ones.
Die Frage bezog sich aufs EBITDA! Zudem stellt das EBITDA den operativen Profit dar - als anerkennte Größe. Daher gehört auch zu den am weitesten verbreiteten Multiples der EV/EBITDA. Wenn also die Rede von Profitabilität ist, dann heißt das nicht unbedingt Net Income (Jahresüberschuss), sondern auch FCF oder EBITDA oder EBIT. Dafür muss man sich den Kontext anschauen!
|